related_education

Progressive Supranuclear Palsy Trial of Plasma Transfusions

Young healthy male donor plasma is commonly used to correct clotting deficiencies, but this is the first time it will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of donor plasma transfusions in patients with PSP.

Summary

  • Study director: Richard Tsai, MD, MBA
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy

Frontotemporal Dementia with Granulin Mutation Trial of a Histone Deacetylase Inhibitor

The aim of this trial is to evaluate the safety and tolerability of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin mutation and to see if it causes a change in plasma concentrations of progranulin.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: FORUM Pharmaceuticals
  • Recruiting?: No
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

Huntington’s Disease Trial of Laquinimod (LEGATO-HD)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of laquinimod which is hypothesized to decrease inflammatory processes that occur in the brain in Huntington’s disease.

Summary

  • Study director: Michael Geschwind, MD, PhD
  • Sponsor: Teva Branded Pharmaceutical Products R&D, Inc
  • Recruiting?: February 2015
  • Official study title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease

Familial Progressive Supranuclear Palsy (FamPSP)

The goal of this study is to identify rare genetic variants as risk factors for progressive supranuclear palsy (PSP). By studying patients with PSP and their relatives affected by related conditions, we hope to identify genes that are involved in PSP and related disorders.

Summary

Purpose of Study

Early Onset and Atypical Alzheimer’s Disease

Approximately 5% of patients with Alzheimer’s disease develop symptoms before age 65, without a known genetic cause. In this study, we use comprehensive clinical evaluations, cerebrospinal fluid (optional) and genetic analyses, and MRI and PET imaging to improve our understanding and diagnosis of early onset and atypical Alzheimer’s disease.

Summary

  • Study director: Gil Rabinovici, MD
  • Sponsor: National Institute on Aging
  • Official study title: Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration

Care Ecosystem: Navigating Patients and Families through Stages of Care

Most dementia care today is crisis-oriented, intermittent and impersonal. The Care Ecosystem is a proactive model that emphasizes coordinated, continuous, and personalized care and aims to improve health and satisfaction for patients and their caregivers. The intervention will also try to reduce avoidable emergency room visits and hospitalizations, and delay entry into a nursing home.

 

Enrolling now! (click to see if you qualify)

 

Corticobasal Syndrome or Progressive Supranuclear Palsy Phase 1 Trial of TPI-287

Tau is a microtubule-associated protein, and abnormal tau function has been proposed to play a role in the development and progression of primary four repeat tauopathies, CBS and PSP. TPI-287 is a stabilizer of microtubule dynamics, and the stabilization of microtubules is hypothesized to compensate for the loss of tau function in primary four-repeat tauopathies. The purpose of this study is to determine the safety and tolerability of intravenous (IV) infusions of TPI-287 in patients with four-repeat tauopathies (4RT), CBS or PSP.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: UCSF (Funder: CBD Solutions, Tau Consortium)
  • Recruiting?: Yes

Asymptomatic Alzheimer’s Disease Anti-Amyloid Trial

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (the protein that forms plaques in the brains of people with Alzheimer’s disease) as compared with placebo in subjects with preclinical AD.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Eli Lilly & Company and National Institute on Aging (NIA)
  • Recruiting?: Yes
  • Official study title: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
  • ClinicalTrials.gov identifier: NCT02008357

Alzheimer’s Disease Trial of Levetiracetam

The purpose of this study is to evaluate whether the anti-epileptic drug levetiracetam reduces subclinical (clinically silent) epileptiform activity and improves cognition in people with Alzheimer’s disease. Epileptiform activity is a term used to describe the abnormal firing of neurons in ways similar to epilepsy or seizure disorder.

Summary

  • Study director: Keith Vossel, MD, MSc
  • Sponsor: Alzheimer’s Association, Inc.; NIH National Institute on Aging; S.D. Bechtel, Jr. Foundation
  • Recruiting?: Yes
  • Official study title: A Phase 2A Levetiracetam Trial for Alzheimer’s Disease—Associated Network Hyperexcitability

Frontotemporal Dementia with Granulin Mutation Trial with Nimodipine

The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: UCSF (funded by the Bluefield Project to Cure FTD)
  • Recruiting?: Not recruiting
  • Official study title: An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency from GRN Gene Mutations
Syndicate content